Valeant's eye chart

With the acquisition of Visudyne verteporfin from QLT Inc. (TSX:QLT; NASDAQ:QLTI), Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) is once again betting it can resurrect an ophthalmic drug that had been left by the roadside following approval of Lucentis ranibizumab from Genentech Inc.